PT  - JOURNAL ARTICLE
AU  - Tal Noy-Porat
AU  - Efi Makdasi
AU  - Ron Alcalay
AU  - Adva Mechaly
AU  - Yinon Levy
AU  - Adi Bercovich-Kinori
AU  - Ayelet Zauberman
AU  - Hadas Tamir
AU  - Yfat Yahalom-Ronen
AU  - Ma’ayan Israeli
AU  - Eyal Epstein
AU  - Hagit Achdout
AU  - Sharon Melamed
AU  - Theodor Chitlaru
AU  - Shay Weiss
AU  - Eldar Peretz
AU  - Osnat Rosen
AU  - Nir Paran
AU  - Shmuel Yitzhaki
AU  - Shmuel C. Shapira
AU  - Tomer Israely
AU  - Ohad Mazor
AU  - Ronit Rosenfeld
TI  - Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
AID  - 10.1101/2020.05.20.106609
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.05.20.106609
4099  - http://biorxiv.org/content/early/2020/06/15/2020.05.20.106609.short
4100  - http://biorxiv.org/content/early/2020/06/15/2020.05.20.106609.full
AB  - The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD, therefore they represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection.Competing Interest StatementPatent application for the described antibodies was filed by the Israel Institute for Biological Research.